Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)
NCT07362836
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
224
Enrollment
OTHER
Sponsor class
Conditions
Colorectal Cancer
Interventions
DRUG:
fruquintinib+chemotherapy
DRUG:
bevacizumab+chemotherapy
Sponsor
Fudan University